MAPT and early-onset autosomal dominant Alzheimer disease: Tau positron emission tomography (PET), which provides the topographic distribution of tau aggregates in the brain, would be useful for the diagnosis of Alzheimer’s disease (AD) and for the assessment of tau burden in the clinical trials of antidementia drugs.